AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors

• Nobuaki Suzuki,
• Tadashi Matsushita,
• Keiji Nogami,
• Azusa Nagao,
• Chiai Nagae,
• Haruko Yamaguchi-Suita,
• Yui Kyogoku,
• Akiko Ioka

Affiliations

Nobuaki Suzuki

Aff150 grid.268397.10000000106607960Department of Gastroenterological, Breast and Endocrine SurgeryYamaguchi University Graduate School of Medicine Ube Japan

Tadashi Matsushita

Blood Transfusion Service, Nagoya University Hospital, Nagoya, Japan

Keiji Nogami

Pediatrics, Nara Medical University, Kashihara, Japan

Azusa Nagao

Ogikubo Hospital, Tokyo, Japan

Chiai Nagae

St Marianna University School of Medicine, Kawasaki, Japan

Haruko Yamaguchi-Suita

Chugai Pharmaceutical Co Ltd, Tokyo, Japan

Yui Kyogoku

Chugai Pharmaceutical Co Ltd, Tokyo, Japan

Akiko Ioka

Chugai Pharmaceutical Co Ltd, Tokyo, Japan